By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers.

The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement.

Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.